Can the CD4+/CD8+ ratio predict the outcome of interferon-α therapy for renal cell carcinoma?

Annals of Oncology

Volumn 8, Issue 1, 1997, Pages 71-77

  Hernberg, M ^a   Muhonen, T ^a   Pyrhonen S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CD4 CD8 ratio; interferon therapy; lymphocyte subsets; metastatic renal cell carcinoma; prognosis

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; VINBLASTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CD4-CD8 RATIO; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; LIFE TABLES; MALE; MIDDLE AGED; NEPHRECTOMY; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0031051536     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008293117223     Document Type: Article

References (31)

1. DeKernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 1978; 120: 148-52.
2. Savage P, Muss H. Renal cell cancer. In DeVita JVT, Hellman S, Rosenberg S (eds): Biologic Therapy of Cancer, 2nd edition. Philadelphia: Lippincott Company 1995; 373-4.
3. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J Urol 1977; 118: 538-42.
4. Quesada JR, Swanson DA, Gutterman JU. Phase II study of interferon alpha in metastatic renal-cell carcinoma: A progress report. J Clin Oncol 1985; 3: 1086-92.
5. DeKernion JB, Sarna G, Figlin R et al. The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 1983; 130: 1063-6.
6. Rosenberg SA. Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
7. Pyrhönen S, Salminen E. Lehtonen Tet al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma. A phase III study. Proc Am Soc Clin Oncol 1995; 686: 410 (Abstr).
8. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10: 1919-26.
9. Muhonen T, Hahka-Kemppinen M, Pakkala S, Pyrhönen S. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. J Immunother 1994; 15: 67-73.
10. Hernberg M, MuhonenT, Turunen JP et al. The CD4+/CD8+ ratio as a prognostic factor in patients treated with chemo-immunotherapy with metastatic melanoma. J Clin Oncol 1996; 14: 1690-6.
11. Knapp W. Leukocyte typing IV. IVth International Workshop and Conference on Human Leukocyte Differentiation Antigens. Vienna, 1989.
12. Jackson AL, Warner NL. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In Rose NR, Friedman H, Fahey JL (eds): Manual of Clinical Immunology, 3rd edition. Washington DC: American Society of Microbiology 1986; 226-35.
13. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989; 52: 48-60.
14. Nicholson JKA. Immunophenotyping specimens from HIV-infected persons: Laboratory guidelines from the centers for disease control and prevention. Cytometry 1994; 18: 55-9.
15. Kirkwood JM, Ernstoff MS. Potential applications of interferons in oncology. Semin Oncol 1986; 13: 48-56.
16. Dadian G, Riches PG, Henderson DC el al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 1994; 74: 15-22.
17. Belldegrun A, Koo AS, Bochner B et al. Immunotherapy for advanced renal cell cancer: The role of radical nephrectomy. Eur Urol 1990; 2: 42-5.
18. Aulitzky WE, Lerche J, Thews A et al. Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden. Eur J Cancer 1994; 30A: 940-5.
19. Grups JW, Frohmuller HG. Influence of cyclic interferon gamma on lymphocytes and their subpopulations in patients with renal carcinoma. Urology 1990; 35: 111-3.
20. Aulitzky WE, Aulitzky W, Gastl G et al. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interferon Res 1989; 9: 425-33.
21. Morisaki T, Morton DL, Uchiyama A et al. Characterization and augmentation of CD4+ cytotoxic T-cell lines against melanoma. Cancer Immunol Immunother 1994; 39: 172-8.
22. Cohen PA, Kim H, Fowler DH et al. Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T-cells in culture with maintained antigen specificity. J Immunother 1993; 14: 242-52.
23. Abrams JS, Eiseman JL, Melink TJ et al. Immunomodulation of interleukin-2 by cyclophosphamide: A phase IB trial. J Immunother 1993; 14: 56-64.
24. Bast RJ, Reinherz EL, Maver C et al. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 1983; 28: 101-14.
25. Hoon DS, Foshag LJ, Nizze AS et al. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50: 5358-64.
26. Mitchell MS. Kempf RA, Harel W et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected] [published erratum appeared in J Clin Oncol 1988; 6(6): 1067]. J Clin Oncol 1988; 6: 409-24.
27. Atzpodien J, Korfer A, Franks CR et al. Home therapy with recombinant interleukin-2 and interferon-alpha-2b in advanced human malignancies. Lancet 1990; 335: 1509-12.
28. Bergmann L, Fenchel K, Weidmann E et al. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 1993; 72: 1733-42.
29. Lipton A, Harvey H, Givant E et al. Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma. J Immunother 1993; 13: 122-9.
30. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863-74.
31. Ernstoff MS, Gooding W, Nair S et al. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992; 52: 851-6.